文献速递肝病

Cilofexor与Firsocostat联合治疗NASH相关桥接纤维化与肝硬化

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
PubMed 文献 · Hepatology · 2021-01-01

这项2b期试验将392例F3-F4期NASH患者随机分配至安慰剂、selonsertib 18 mg、cilofexor 30 mg或firsocostat 20 mg单药或两药联合组,治疗48周。主要终点为纤维化改善≥1期且NASH不恶化,各组均未显著优于安慰剂;cilofexor/firsocostat联合组在NAS评分、肝酶及非侵入性指标方面显著改善,且耐受性良好。

要点

  • cilofexor/firsocostat联合组纤维化改善≥1期比例为21%,安慰剂组为11%,差异未达统计学显著(P=0.17)。
  • cilofexor/firsocostat联合组ML NASH CRN纤维化评分显著下降(P=0.040),肝活检模式从F3-F4向≤F2转变。
  • cilofexor/firsocostat联合组NAS≥2分改善比例及ALT、AST、胆红素、胆汁酸等指标均显著优于安慰剂(P≤0.05)。

核心结论

  • 在桥接纤维化和肝硬化NASH患者中,cilofexor/firsocostat联合治疗48周耐受性良好,改善NASH活动度,并可能具有抗纤维化作用。

研究设计与样本

  • 2b期随机对照试验,纳入392例桥接纤维化或代偿性肝硬化(F3-F4)患者,随机接受安慰剂、selonsertib 18 mg、cilofexor 30 mg或firsocostat 20 mg单药或两药联合,每日一次,治疗48周。
  • 主要终点为48周时基于中心病理学家评估的纤维化改善≥1期且NASH不恶化。

主要发现

  • 主要终点达成率:安慰剂11%,cilofexor/firsocostat 21%(P=0.17),cilofexor/selonsertib 19%(P=0.26),firsocostat/selonsertib 15%(P=0.62),firsocostat 12%(P=0.94),cilofexor 12%(P=0.96)。
  • cilofexor/firsocostat组ML NASH CRN纤维化评分显著下降(P=0.040),肝活检面积从F3-F4向≤F2模式转变。
  • 与安慰剂相比,cilofexor/firsocostat组NAS≥2分改善比例、脂肪变、小叶炎症和气球样变减少比例显著更高,ALT、AST、胆红素、胆汁酸、细胞角蛋白-18、胰岛素、eGFR、ELF评分及瞬时弹性成像肝硬度均显著改善(所有P≤0.05)。
  • 瘙痒发生率:cilofexor组20%-29%,安慰剂组15%。

关键数值与推荐

  • 主要终点未达统计学显著:cilofexor/firsocostat组21% vs 安慰剂组11%,P=0.17。
  • cilofexor/firsocostat组ML NASH CRN纤维化评分下降P=0.040。
  • cilofexor/firsocostat组NAS≥2分改善及ALT、AST、胆红素、胆汁酸等指标改善均P≤0.05。

临床怎么用

  • cilofexor/firsocostat联合治疗可能作为NASH相关晚期纤维化患者长期治疗的潜在选择,但主要纤维化终点未达显著,需进一步研究。
  • 治疗期间需关注瘙痒不良反应,cilofexor组瘙痒发生率高于安慰剂。

局限性

  • 主要终点未达到统计学显著差异。
  • 原文未报告样本量计算、随访时间延长及长期临床结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS: In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or firsocostat 20 mg, alone or in two-drug combinations, once-daily for 48 weeks. The primary endpoint was a ≥1-stage improvement in fibrosis without worsening of NASH between baseline and 48 weeks based on central pathologist review. Exploratory endpoints included changes in NAFLD Activity Score (NAS), liver histology assessed using a machine learning (ML) approach, liver biochemistry, and noninvasive markers. The majority had cirrhosis (56%) and NAS ≥5 (83%). The primary endpoint was achieved in 11% of placebo-treated patients versus cilofexor/firsocostat (21%; P = 0.17), cilofexor/selonsertib (19%; P = 0.26), firsocostat/selonsertib (15%; P = 0.62), firsocostat (12%; P = 0.94), and cilofexor (12%; P = 0.96). Changes in hepatic collagen by morphometry were not significant, but cilofexor/firsocostat led to a significant decrease in ML NASH CRN fibrosis score (P = 0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns. Compared to placebo, significantly higher proportions of cilofexor/firsocostat patients had a ≥2-point NAS reduction; reductions in steatosis, lobular inflammation, and ballooning; and significant improvements in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, bile acids, cytokeratin-18, insulin, estimated glomerular filtration rate, ELF score, and liver stiffness by transient elastography (all P ≤ 0.05). Pruritus occurred in 20%-29% of cilofexor versus 15% of placebo-treated patients. CONCLUSIONS: In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Loomba R, Noureddin M, Kowdley KV, et al. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021. PMID: 33169409. doi:10.1002/hep.31622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。